This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruhe, J. E. Articles by Ullrich, A. Search for Related Content PubMed PubMed Citation Articles by Ruhe, J. E. Articles by Ullrich, A.

Genetic Alterations in the Tyrosine Kinase Transcriptome of Human Cancer Cell Lines

¹ Institute of Medical Biology, ² Bioinformatics Institute, and ³ Institute of Molecular and Cell Biology, Singapore, Singapore; ⁴ Department of Pathology, Technical University of Munich, Munich, Germany; ⁵ Max-Planck-Institute for Biochemistry, Martinsried, Germany; ⁶ Department of Oncology, University of Chieti Medical School, Chieti, Italy; and ⁷ Department of Urology, Klinikum Darmstadt, Darmstadt, Germany

Requests for reprints: Jens E. Ruhe, U3 Pharma AG, Bunsenstrasse 1, 82152 Martinsried, Germany. E-mail: ruhe{at}u3pharma.com.

Protein tyrosine kinases (PTKs) play a critical role in the manifestation of cancer cell properties, and respective signaling mechanisms have been studied extensively on immortalized tumor cells. To characterize and analyze commonly used cancer cell lines with regard to variations in the primary structure of all expressed PTKs, we conducted a cDNA-based sequence analysis of the entire tyrosine kinase transcriptome of 254 established tumor cell lines. The profiles of cell line intrinsic PTK transcript alterations and the evaluation of 155 identified polymorphisms and 234 somatic mutations are made available in a database designated "Tykiva" (tyrosine kinome variant). Tissue distribution analysis and/or the localization within defined protein domains indicate functional relevance of several genetic alterations. The cysteine replacement of the highly conserved Y367 residue in fibroblast growth factor receptor 4 or the Q26X nonsense mutation in the tumor-suppressor kinase CSK are examples, and may contribute to cell line–specific signaling characteristics and tumor progression. Moreover, known variants, such as epidermal growth factor receptor G719S, that were shown to mediate anticancer drug sensitivity could be detected in other than the previously reported tumor types. Our data therefore provide extensive system information for the design and interpretation of cell line–based cancer research, and may stimulate further investigations into broader clinical applications of current cancer therapeutics. [Cancer Res 2007;67(23):11368–76]

This article has been cited by other articles:

				Y. Zhang, M. J. Italia, K. R. Auger, W. S. Halsey, S. F. Van Horn, G. M. Sathe, M. Magid-Slav, J. R. Brown, and J. D. Holbrook Molecular Evolutionary Analysis of Cancer Cell Lines Mol. Cancer Ther., February 1, 2010; 9(2): 279 - 291. [Abstract] [Full Text] [PDF]

				N. Seitzer, T. Mayr, S. Streit, and A. Ullrich A Single Nucleotide Change in the Mouse Genome Accelerates Breast Cancer Progression Cancer Res., January 15, 2010; 70(2): 802 - 812. [Abstract] [Full Text] [PDF]

				O. Simma, E. Zebedin, N. Neugebauer, C. Schellack, A. Pilz, S. Chang-Rodriguez, K. Lingnau, E. Weisz, E. M. Putz, W. F. Pickl, et al. Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance Cancer Res., January 1, 2009; 69(1): 203 - 211. [Abstract] [Full Text] [PDF]